For the first quarter of the fiscal year ending March 2027, consolidated net sales were 90,672 million yen (YoY +8.1%), operating income was 10,413 million yen (+171.0% YoY), and net income for the period was 6,293 million yen, indicating solid performance. Segments such as Diabetes Management, Clinical Testing & CRO, and Pathology & Life Sciences contributed. Full-year guidance unchanged.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6523","jir_company_name":"PHC Holdings Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/6523-20260806-01.pdf","jir_short_summary":"For the first quarter of the fiscal year ending March 2027, consolidated net sales were 90,672 million yen (YoY +8.1%), operating income was 10,413 million yen (+171.0% YoY), and net income for the period was 6,293 million yen, indicating solid performance. Segments such as Diabetes Management, Clinical Testing & CRO, and Pathology & Life Sciences contributed. Full-year guidance unchanged.","jir_summary":"### Performance overview\nThis quarter posted net sales of 90,672 million yen (YoY +8.1%) and operating income of 10,413 million yen (YoY +171.0%), marking a substantial profit increase. By segment, Diabetes Management, Clinical Testing & CRO, and Pathology & Life Sciences showed solid momentum, supported by foreign exchange effects and cost reductions. Equity in earnings of affiliates was -28 million yen, net income for the period was 6,293 million yen, and net income attributable to owners of the parent turned positive to 6,338 million yen.\n\n### Outlook and material matters\nFor the full-year fiscal year ending March 2027, there is no revision to the latest outlook; the current assumptions are kept. As drivers of segment strength, demand recovery, price revisions, and exchange rate effects in the U.S., Europe, and developing markets are expected to continue. Preparation of the earnings supplement materials and an earnings briefing are planned.","jir_financial_highlights":"Net sales: 90,672 (YoY +8.1%)\nOperating income: 10,413 (YoY +171.0%)\nProfit before tax for the quarter: 8,133 (YoY substantially black)\nNet income attributable to owners of the parent: 6,338 (Prior year quarter was a loss)\nBasic earnings per share (diluted not specified): 50.06 (Prior year quarter was -18.55 yen)\nTotal net sales by segment: 83,789 (YoY increase)","jir_category":"","jir_hashtags":"#PHCHoldings, #DiabetesManagement, #ClinicalTesting, #LifeSciences, #FinancialResults","jir_key_figures":"Net sales: 90,672\u767e\u4e07\u5186\nOperating income: 10,413\u767e\u4e07\u5186\nNet income attributable to owners of the parent: 6,338\u767e\u4e07\u5186","jir_meta_title":"PHC Holdings Corporation Q1 FY2027 Financial Results \u2014 Revenue and Profit Expand toward \u00a59 trillion scale","jir_meta_description":"PHC Holdings Corporation's Q1 FY2027 financial results show net sales of 90,672 million yen and operating income of 10,413 million yen with substantial year-over-year growth. A summary of segment contributions, full-year prospects, and the earnings briefing schedule.","jir_og_title":"PHC Holdings Q1 Financial Results Announced \u2014 Robust Revenue and Significant Profit Growth","jir_og_description":"PHC Holdings' Q1 FY2027 results show net sales of 90,672 million yen and operating income of 10,413 million yen. An explanation of segment performance and future outlook.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9274,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-97566","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n